🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)

RecruitingPhase 4Ages 18 Years - anyAllNatasha Appelman-Dijkstra
NCT05966064 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Fibrous Dysplasia/McCune-Albright syndrome (FD/MAS) is a rare disease, consisting of the replacement of normal bone tissue with fibrous tissue. FD lesions may be isolated in one or more bones or may be associated with endocrinopathies in McCune-Albright syndrome. Bone lesions constitute of weak bone tissue, leading to higher risk of fractures, pain and decreased quality of life. There is no cure for FD lesions and current therapies failed to soothe patients' complaints or to display any effect on progression of the lesions on imaging. However, the RANKL-inhibitor Denosumab demonstrated encouraging results in mouse models and in off-label clinical use, leading to clinical, biochemical and radiographical improvements. Study's aim is to investigate whether 3-monthly Denosumab will improve the clinical, radiological and biochemical manifestations of FD bone lesions.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Symptomatic patients with established diagnosis of FD/MAS and closed growth plates(\>18 years) * Pain in the region of an FD localization, not responding to adequate pain treatment and without mechanical component e.g. impending fracture * Pain score from FD lesion for maximum or average pain on VAS ≥ 4 * Increased lesional activity defined as increased bone turnover markers (ALP, P1NP or CTX) or increased activity on Na\[18F\]-PET/CT or bone scintigraphy in at least one lesion * Normal levels of calcium, parathyroid hormone and vitamin D (supplementation is allowed) * Treated hypophosphatemia (defined as \>0.7 at two separate measures) * good dental health (last check within the last 12 months) Exclusion Criteria: * Active pregnancy wish, pregnancy or nursing * Pain not related to FD * Uncontrolled endocrine disease * Untreated vitamin D deficiency, hypocalcemia or hypophosphatemia * Previous use of bisphosphonates or Dmab \< 6 months before inclusion ('6 months wash out') * Previously reported severe side effects on Dmab * Inability to fulfil study requirements * Poor untreated dental health without intention to get treatment * Treatment with other bone influencing drugs, such as high doses corticosteroids
💊

What it tests

  • Denosumab 120 Mg/1.7 Ml Inj
  • Placebo
📍

Where

1 site
Leiden University Medical Center
Leiden, Netherlands
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy